Protocols›Metabolic & fat loss›Oral GLP-1 · Foundayo
← Protocols
Oral · once-dailyNeedle-free · GLP-1 entryFDA-approved (US)

Oral GLP-1 · Foundayo

Stack: Orforglipron · the needle-free, once-daily entry to the incretin class
"The injection-free counterpart to the GLP-1 Foundation. Orforglipron (Foundayo) is a small-molecule GLP-1 pill — FDA-approved in April 2026, taken once daily with no food or water rules. Like semaglutide, the honest issue isn't whether it works; it's that it's prescription-only, carries a boxed thyroid warning, and isn't UK-approved yet."
GoalWeight loss / glycaemic control · oral
Compounds1 · Orforglipron
Human evidenceStrong — Phase 3 (ATTAIN / ACHIEVE)
StatusFDA (US): approved 1 Apr 2026 (Foundayo) · MHRA (UK): approved 10 Aug 2026 — prescription only in both. Any UK supply outside a prescription is outside the licensed chain, and a pill is easy to counterfeit
In this stack — snapshot; tap through for the full molecule file
Provenance & evidence layers — of the combination, not the parts
Approved clinical use (US)
Where / who
FDA-approved on 1 April 2026 as Foundayo for chronic weight management in adults with obesity, or overweight with a weight-related condition — alongside diet and activity.
Status
A fully approved medicine in the US (1 Apr 2026) and the UK (MHRA, 10 Aug 2026) with an approved label and pharmacovigilance — the opposite of a research compound.
Evidence it adds
Regulator-grade efficacy and safety — for the licensed product, used as directed.
Basis: FDA approval (Foundayo, Apr 2026)
Clinical trial evidence
Weight
The ATTAIN programme: roughly 11% mean weight loss at the higher doses over 72 weeks — meaningful, though generally below peak injectable figures.
Glycaemic
ACHIEVE (type 2 diabetes); a head-to-head in The Lancet had oral orforglipron beat oral semaglutide on both glucose and weight.
Evidence it adds
Controlled Phase 3 human efficacy and safety data — the strongest tier in this catalogue.
Basis: ATTAIN, ACHIEVE, Lancet head-to-head
Grey-market / unsupervised use
Where / who
Ahead of UK approval, some will source it outside any prescription. A swallowed small-molecule tablet is comparatively easy to counterfeit convincingly.
What changes
Supervision, dose titration and — critically — product identity are no longer controlled. An unverified pill cannot be confirmed for identity or dose.
Evidence it adds
None on efficacy — this layer is about how unsupervised use diverges from the trials.
Basis: real-world sourcing patterns — not a trial tier
Regulatory — read carefully
MHRA (UK)
Not yet approved. The MHRA granted orforglipron a UK marketing authorisation on 10 August 2026 (prescription-only) — so the licensed UK route is a prescription, and any supply outside it is unlicensed.
FDA (US)
Approved 1 Apr 2026, prescription-only. Carries a boxed warning for thyroid C-cell tumours (MTC); contraindicated with personal/family history of MTC or MEN-2.
What it means
Approved in the US does not mean available or lawful to source in the UK — and the safety record belongs to the prescribed product.
Basis: FDA approval · MHRA authorisation (10 Aug 2026) · boxed warning
Why this is the foundation

Orforglipron is the needle-free way into the GLP-1 class. Because it is a non-peptide small molecule, it survives the gut and works as an ordinary once-daily tablet — taken any time of day, with or without food or water, unlike the strict rules oral semaglutide needs. The trade-off is that peak weight loss (~11% in ATTAIN) generally sits below the strongest injectables. The honest framing matches the injectable Foundation: the question isn't whether it works, it's whether it's run the way the evidence was generated — prescribed, titrated and supervised — or sourced as an unverified pill, in a market where it isn't UK-approved yet.

Members only · the actionable depth
See exactly how it's run
Doses, titration structure and what to monitor are part of membership. The provenance, evidence and status above are always free.
Get TiQ1 · Free →
Free · just create an account
Cycle shape — how it's typically structured, not a schedule to follow
Titration
0.8 mg → up, ≥30-day steps
Maintenance
effective dose (max 17.2 mg)
Review
continue / adjust
The FDA label starts at 0.8 mg once daily and steps up no faster than every 30 days (2.5 → 5.5 → 9 → 14.5 → 17.2 mg) to manage GI side-effects — this mirrors the licensed schedule, not a prescription to follow.
What's worth monitoring

Orforglipron has a defined clinical monitoring picture: GI tolerance during titration; a boxed thyroid C-cell warning (contraindicated with personal/family history of MTC or MEN-2); muscle-mass loss alongside fat loss; and CYP3A4 drug interactions (max 9 mg with a strong inhibitor). It's a CYP3A4 substrate, so review concomitant medicines. The licensed product is monitored by a prescriber; outside that route, no one is — and in the UK there is no licensed route yet. Baseline bloods and a clinician conversation are the sensible floor. General information, not medical advice.

Evidence
Human efficacy Strong

Phase 3 (ATTAIN / ACHIEVE) — ~11% mean weight loss over 72 weeks; beat oral semaglutide head-to-head in T2D.

Approval Strong

FDA-approved 1 Apr 2026 and MHRA-approved 10 Aug 2026 (Foundayo) — approved label and pharmacovigilance in both. Prescription-only.

Unsupervised use Risk shifts

A pill is easy to counterfeit; an unverified tablet can't be confirmed for identity or dose — and it isn't UK-approved.

The honest point

Proven and US-approved. The harm-reduction question is the supply route — and, in the UK, the missing licence.

Fast facts
Compounds

Orforglipron

Brand

Foundayo (Eli Lilly)

UK strip

AMBER — prescription only medicine (MHRA-approved 10 Aug 2026)